Search clinical trials for: ND0612 (Levodopa/Carbidopa solution) morning oral IR-LD/CD

Total 22 results

NeuroDerm Ltd.

Active, not recruiting

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

Parkinson's Disease

United States, Israel, Spain, France, Russian Federation, Austria, Italy, Belgium, Czechia, Hungary, Netherlands, Poland, Portugal, Slovakia, Ukraine, United Kingdom
NeuroDerm Ltd.

Completed

A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

Parkinson's Disease

United States, Israel, Italy, Austria
Impax Laboratories, LLC

Completed

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Impax Laboratories, LLC

Completed

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

Parkinson's Disease

United States, Canada, France, Germany, Poland, Romania, Spain, Ukraine
Impax Laboratories, LLC

Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

Parkinson's Disease

United States
Intec Pharma Ltd.

Unknown

A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients (Accordance)

Parkinson's Disease

United States, Spain, Italy, Israel, Poland, United Kingdom, Bulgaria, Germany, Slovakia, Ukraine
AbbVie

Completed

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia
Impax Laboratories, LLC

Completed

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

Parkinson's Disease

United States
Impax Laboratories, LLC

Completed

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

Parkinson's Disease (Disorder)

United States, Czechia, France, Italy, Spain, Germany, Poland, United Kingdom
Impax Laboratories, LLC

Completed

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease (APEX-PD)

Parkinson's Disease

United States, Canada, Estonia, Latvia, Lithuania, Romania, Ukraine
Impax Laboratories, LLC

Completed

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

Parkinson's Disease

United States, Canada, Estonia, Latvia, Lithuania, Romania, Ukraine, Germany, Poland, Spain
Impax Laboratories, LLC

Completed

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

Advanced Parkinson's Disease

United States
NeuroDerm Ltd.
Quotient Clinical

Completed

A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects

Parkinson's Disease

United Kingdom
NeuroDerm Ltd.

Withdrawn

A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations

Parkinson's Disease

Israel
Intec Pharma Ltd.

Unknown

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

Parkinson's Disease

United States, Israel, Italy, Spain, United Kingdom, Bulgaria, Germany, Poland, Slovakia, Ukraine
IRCCS San Raffaele Roma
SynAgile Corporation

Completed

Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients (LDCD-001)

Parkinson Disease

Italy
NeuroDerm Ltd.

Completed

A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients

Parkinson's Disease

Israel
Intec Pharma Ltd.

Unknown

Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients

Parkinson Disease
NeuroDerm Ltd.
Michael J. Fox Foundation for Parkinson's Research

Completed

A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients

Parkinson's Disease

Israel
AbbVie (prior sponsor, Abbott)
Quintiles, Inc.

Completed

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Advanced Parkinson's Disease

United States, Germany
AbbVie (prior sponsor, Abbott)
Quintiles, Inc.

Completed

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Advanced Parkinson's Disease

United States, New Zealand
Impax Laboratories, LLC
Michael J. Fox Foundation for Parkinson's Research

Completed

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

Parkinson's Disease

United States

3

Subscribe